Two of The American Journal of Managed Care®'s top 5 most-read news stories were themselves top-5 roundups of hot topics in healthcare this year. The list was rounded out by cardiovascular, diabetes, and cancer news.
Two of The American Journal of Managed Care'® (AJMC®)’s top 5 most-read news stories were themselves top-5 roundups of hot topics in healthcare. The list was rounded out by cardiovascular, diabetes, and cancer news.
And 2 of the 5 stories were related to health technology, with one providing a general look at wearables and another about the Freestyle Libre continuous glucose monitoring (CGM) system for patients with diabetes.
5. 5 Vulnerable Populations in Healthcare
For vulnerable populations, health and healthcare issues may be exacerbated by social factors; as a result, they experience worse access to care and increased morbidity and mortality compared with the general population. While a number of vulnerable populations exist, these 5 groups experience greater healthcare disparities: those who are chronically ill and disabled; low-income and/or homeless individuals; certain geographical communities; the LGBTQ+ population; and the very young and very old.
4. 5-Year Survival Rates for Patients With Cancer Worldwide
Using a global surveillance program that documents cancer survival trends, researchers determined the 5-year survival rates of patients diagnosed with 18 types of cancer worldwide. CONCORD-3 includes the records of 37.5 million patients diagnosed with cancer from 2000 to 2014, 322 population-based cancer registries in 71 countries and territories, and data on patients’ vital status at least 5 years following diagnosis.
3. ODYSSEY Outcomes Results for Sanofi’s Praluent to Lead Off ACC Meeting
A preview of the 2018 American College of Cardiology meeting, with a focus on the cardiovascular outcomes results for the PCSK9 inhibitor alirocumab (Praluent) from the ODYSSEY Outcomes trial, was the third most-read story of the year. ODYSSEY sought to determine whether Sanofi-Regeneron’s alirocumab (Praluent) had a superior cardiovascular benefit to Amgen’s evolocumab (Repatha).
2. 5 Things About Wearable Technology in Healthcare
The second most-read story of this year was a look at 5 things to know about wearable technology and healthcare. From consumer gadgets to medical devices that are FDA approved, wearables have implications for cardiology, diabetes, medical adherence, clinical trials, and more.
1. Abbott's Freestyle Libre CGM Gains Medicare Coverage
2018 kicked off with Abbott winning Medicare coverage for its Freestyle Libre CGM system, which requires no regular finger sticks. To receive coverage for therapeutic CGM, a Medicare beneficiary must have type 1 diabetes or be receiving intensive insulin therapy for type 2 diabetes; those eligible must document that their condition requires frequent insulin dosing adjustments, based on checking blood glucose levels at least 4 times a day. Interestingly, Medicare’s 2017 first ruling in favor of CGMs (albeit without allowing the use of smartphones) was the number 1 AJMC® story that year, as well.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Real-World Data Show Leqvio's Effectiveness in Reducing LDL-C in Patients With ASCVD
April 11th 2024Results from the V-INITIATE trial showed a substantial 60% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 in the inclisiran first group compared with a mere 7% reduction in the usual care group.
Read More